(Q32040849)

5 July 2017

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial (English)

1 reference

5 July 2017

phase II clinical trial

0 references

author name string

S M Tu

1

1 reference

5 July 2017

R E Millikan

2

1 reference

5 July 2017

B Mengistu

3

1 reference

5 July 2017

E S Delpassand

4

1 reference

5 July 2017

R J Amato

5

1 reference

5 July 2017

L C Pagliaro

6

1 reference

5 July 2017

D Daliani

7

1 reference

5 July 2017

C N Papandreou

8

1 reference

5 July 2017

T L Smith

9

1 reference

5 July 2017

J Kim

10

1 reference

5 July 2017

D A Podoloff

11

1 reference

5 July 2017

C J Logothetis

12

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

5 July 2017

1 reference

5 July 2017

357

1 reference

5 July 2017

336-341

1 reference

5 July 2017

9253

1 reference

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Nuclear bone imaging in metastatic cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

False positive rates of randomized phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

Reduced incidence of bone metastases in irradiated areas after external radiation therapy of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903639-4

7 January 2021

10.1016/S0140-6736(00)03639-4

Identifiers

DOI

1 reference

5 July 2017

1 reference